“Add kidney cancer (RCC) to the growing list of individual cancers where the ECS is actively expressed in an attempt to decrease cancer growth. In RCC, specifically CB2R and not CB1R activation cause the cancer cell to die.”
- Dr. David Hepburn
Abstract:
The anti-tumor properties of cannabinoids have been investigated in many in vitro and in vivo studies. Many of these anti-tumor effects are mediated via cannabinoid receptor types 1 and 2 (CB1 and CB2), comprising the endocannabinoid system (ECS).
In thisstudy, the ECS isinvestigatedbasedon CB1 and CB2 receptor gene and protein expression in renal cell carcinoma (RCC) cell lines. In view of their further use for potential treatments, then the roles of CB1 and CB2 receptorswereinvestigatedin the anti-proliferative action and signal transduction triggered by synthetic cannabinoid agonists [such as JWH-133 and WIN 55,212–2 (WIN-55)] in RCC cell lines.
Read the full article here:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966919/
Visit
Dr. Dave Hepburn website: https://doctordavidhepburn.com
0 comments:
Post a Comment